The Federal Trade Commission has paused its case against CVS Caremark to review a proposed consent agreement that would resolve all claims against the company.
The March 23 joint motion from the FTC complaint counsel and CVS Caremark asks the commission to withdraw the matter from adjudication. The agreement, which has already been signed and approved by the FTC’s Bureau of Competition and Bureau of Consumer Protection, would fully resolve the commission’s claims if accepted, according to the filing.
The case is part of a broader FTC crackdown on pharmacy benefit managers. The commission sued CVS Caremark, Optum Rx and Express Scripts in September 2024 over alleged anticompetitive practices. The FTC previously paused the case in April 2025, citing a lack of participating commissioners, and resumed proceedings later that year. It has since reached a separate February 2026 settlement with Express Scripts over insulin pricing, requiring the PBM to overhaul rebate practices and adopt new transparency standards.
Proceedings remain active for Optum Rx and other respondents. The FTC said it will determine next steps for CVS Caremark after reviewing the proposed settlement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
